DATE & TIME
Wednesday, February 25, 2015
5:30 PM – 7:30 PM
Johnson & Johnson Innovation Center
255 Main Street, 7th Floor
Cambridge, MA 02142
Pharma Corporate Venture Capital (CVC) Insights: How CVCs Operate and Deploy Capital
Panel Discussion with Q&A
During the period from 2008-2012, the number of independent venture capital firms investing in biotech shrank significantly. Pharma has filled the gap by becoming a major investor in early stage technology through the growth of corporate venture capital (CVC) investing. By one VC firm’s estimate, CVC investing now accounts for nearly one-third of all life science Series A financings and is growing. In addition, there is data to suggest that start-up companies with CVC investors are more successful than their peers.
Pharma CVCs have been around for nearly forty years and nearly all pharma companies now have a CVC fund. A range of investment philosophies exist for CVC, from standalone funds seeking to maximize return to strategic funds that invest to maximize their portfolio of drugs.
Hear from our panel members firsthand about the philosophy behind their Company’s CVC fund, what issues they consider when making an investment and their insights for small companies seeking access to CVC funding.
Jason P. Hafler, PhD, Director of Investments, Sanofi-Genzyme Bioventures
Martin F. Heidecker, PhD, Boehringer Ingelheim Venture USA Inc.
Marian Nakada, PhD, Vice President Venture Investments, Johnson & Johnson Development Corp.
David Brush, Senior Director Transactions, J&J Innovation Center
LES Member: $25
Online registration deadline: February 24 at 12:00 PM EST
No refunds after February 24
Substitutions are permitted